Kura Oncology, Inc. 8-K

What Happened

• Kura Oncology, Inc. issued a press release on January 11, 2026 and filed a Form 8‑K on January 12, 2026 (Item 2.02) announcing preliminary revenue for KOMZIFTI™ (ziftomenib) and outlining anticipated company milestones for 2026. The press release was furnished as Exhibit 99.1 to the 8‑K.

Key Details

• Date of press release: January 11, 2026; Form 8‑K filed: January 12, 2026.
• Subject: preliminary KOMZIFTI (ziftomenib) revenue and a summary of anticipated 2026 milestones.
• Filing item: Item 2.02 (Results of Operations and Financial Condition); press release provided as Exhibit 99.1.
• The Form 8‑K furnishes the press release; investors should review the release for specific figures and milestone timing.

Why It Matters

• Reporting preliminary revenue for KOMZIFTI signals commercial activity and is a direct indicator of product adoption and sales traction.
• The outlined 2026 milestones provide a roadmap of near‑term operational and development catalysts investors can watch for.
• Because the 8‑K primarily furnishes a press release, retail investors should read that release and await detailed quarterly financial reports for full revenue and earnings disclosures.